Rathmell Kimryn W, Chen Fengju, Creighton Chad J
Department of Urology, University of North Carolina, Chapel Hill, NC ; Department of Genetics, University of North Carolina, Chapel Hill, NC ; Department of Medicine, Division of Hematology and Oncology, University of North Carolina, Chapel Hill, NC.
The Dan L. Duncan Cancer Center Division of Biostatistics, Houston, TX, USA.
Oncoscience. 2015 Feb 20;2(2):81-90. doi: 10.18632/oncoscience.130. eCollection 2015.
Chromophobe Renal Cell Carcinoma (ChRCC) is a rare subtype of the renal cell carcinomas, a heterogenous group of cancers arising from the nephron. Recently, The Cancer Genome Atlas (TCGA) profiled this understudied disease using multiple data platforms, including whole exome sequencing, whole genome sequencing (WGS), and mitochondrial DNA (mtDNA) sequencing. The insights gained from this study would have implications for other types of kidney cancer as well as for cancer biology in general. Global molecular patterns in ChRCC provided clues as to this cancer's cell of origin, which is distinct from that of the other renal cell carcinomas, illustrating an approach that might be applied towards elucidating the cell of origin of other cancer types. MtDNA sequencing revealed loss-of-function mutations in NADH dehydrogenase subunits, highlighting the role of deregulated metabolism in this and other cancers. Analysis of WGS data led to the discovery of recurrent genomic rearrangements involving TERT promoter region, which were associated with very high expression levels of TERT, pointing to a potential mechanism for TERT deregulation that might be found in other cancers. WGS data, generated by large scale efforts such as TCGA and the International Cancer Genomics Consortium (ICGC), could be more extensively mined across various cancer types, to uncover structural variants, mtDNA mutations, themes of tumor metabolic properties, as well as noncoding point mutations. TCGA's data on ChRCC should continue to serve as a resource for future pan-cancer as well as kidney cancer studies, and highlight the value of investigations into rare tumor types to globally inform principals of cancer biology.
嫌色性肾细胞癌(ChRCC)是肾细胞癌的一种罕见亚型,肾细胞癌是一组起源于肾单位的异质性癌症。最近,癌症基因组图谱(TCGA)使用多个数据平台对这种研究较少的疾病进行了分析,包括全外显子组测序、全基因组测序(WGS)和线粒体DNA(mtDNA)测序。这项研究获得的见解对其他类型的肾癌以及一般癌症生物学都有启示意义。ChRCC中的全球分子模式为这种癌症的起源细胞提供了线索,该起源细胞与其他肾细胞癌不同,说明了一种可能用于阐明其他癌症类型起源细胞的方法。mtDNA测序揭示了NADH脱氢酶亚基的功能丧失突变,突出了代谢失调在这种癌症和其他癌症中的作用。对WGS数据的分析导致发现了涉及TERT启动子区域的复发性基因组重排,这些重排与TERT的非常高表达水平相关,指出了一种可能在其他癌症中发现的TERT失调的潜在机制。由TCGA和国际癌症基因组联盟(ICGC)等大规模项目生成的WGS数据,可以在各种癌症类型中进行更广泛的挖掘,以发现结构变异、mtDNA突变、肿瘤代谢特性主题以及非编码点突变。TCGA关于ChRCC的数据应继续作为未来泛癌以及肾癌研究的资源,并突出对罕见肿瘤类型进行研究的价值,以全面了解癌症生物学原理。